Advanced Accelerator Applications (original) (raw)
Advanced Accelerator Applications (AAA), (NASDAQ: AAAP) es un grupo farmacéutico especializado en el campo de la Medicina Nuclear. El grupo opera en los tres segmentos principales de la Medicina Nuclear (PET, SPECT y Terapia) para el diagnóstico y tratamiento de patologías graves en los campos de oncología (cáncer), neurología, cardiología y enfermedades infecciosas e inflamatorias.
| Property | Value |
|---|---|
| dbo:abstract | Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases. In late October 2017, Reuters announced that Novartis would acquire the company for 3.9billion,paying3.9 billion, paying 3.9billion,paying41 per ordinary share and $82 per American depositary share representing a 47 percent premium. On January 22, 2018, Novartis AG announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A. (en) Advanced Accelerator Applications (AAA), (NASDAQ: AAAP) es un grupo farmacéutico especializado en el campo de la Medicina Nuclear. El grupo opera en los tres segmentos principales de la Medicina Nuclear (PET, SPECT y Terapia) para el diagnóstico y tratamiento de patologías graves en los campos de oncología (cáncer), neurología, cardiología y enfermedades infecciosas e inflamatorias. (es) Advanced Accelerator Applications, kurz AAA, ist ein pharmazeutisches Unternehmen, spezialisiert auf dem Gebiet der Nuklearmedizin. Die Gruppe agiert in allen drei Segmenten der molekularen Nuklearmedizin (PET, SPECT und Therapie) zur Diagnose und Behandlung schwerer Erkrankungen in den Bereichen Onkologie (Krebs), Neurologie, Kardiologie, Infektionskrankheiten und entzündlichen Erkrankungen. (de) Advanced Accelerator Applications (AAA) (NASDAQ: AAAP) est un groupe pharmaceutique spécialisé en médecine nucléaire moléculaire. L’activité du groupe est axée sur les 3 segments de la médecine nucléaire moléculaire (la TEP/PET, la TEMP/SPECT et la thérapie) pour le diagnostic et le traitement de maladies oncologiques (cancer), neurologiques, cardiologiques, infectieuses et inflammatoires. La médecine nucléaire moléculaire est une spécialité médicale qui utilise des quantités infimes de substances radioactives appelées radiopharmaceutiques pour le diagnostic et le traitement de maladies. En imagerie médicale nucléaire, les traceurs radiopharmaceutiques sont détectés à l’aide de caméras TEP ou TEMP connectées à des ordinateurs pour produire des images précises de la zone observée. La médecine nucléaire peut permettre le traitement de certains types de cancers et autres maladies. L'imagerie moléculaire permet aux médecins de voir le corps fonctionner et d’évaluer ses processus chimiques et biologiques. Les procédures de médecine nucléaire peuvent souvent identifier des anomalies à des stades précoces dans l'évolution d'une maladie – bien avant la mise en évidence de problèmes médicaux par d’autres tests diagnostiques. (fr) |
| dbo:foundingYear | 2002-01-01 (xsd:gYear) |
| dbo:industry | dbr:Pharmaceutical_industry |
| dbo:keyPerson | dbr:Sidonie_Golombowski-Daffner |
| dbo:location | dbr:Saint-Genis-Pouilly dbr:France |
| dbo:numberOfEmployees | 1000 (xsd:nonNegativeInteger) |
| dbo:parentCompany | dbr:Novartis |
| dbo:wikiPageID | 42427396 (xsd:integer) |
| dbo:wikiPageLength | 17553 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1105561227 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Bombesin dbr:Pharmaceutical dbr:Reuters dbr:SPECT dbr:Saint-Genis-Pouilly dbr:Gastrointestinal_cancer dbr:Midgut dbr:Apoptosis dbr:Lutetium_(177lu)_vipivotide_tetraxetan dbr:Single-photon_emission_computed_tomography dbr:Clinical_trial dbr:Pancreatic_cancer dbr:Pharmaceutical_industry dbr:Progression-free_survival dbr:CERN dbr:Tyrosine dbr:Large_intestine dbr:Acetic_acid_(medical_use) dbr:DOTA-TATE dbr:Food_and_Drug_Administration dbr:France dbr:Breakthrough_therapy dbr:Novartis dbr:Nuclear_medicine dbr:Pancreas dbr:Pancreatic dbr:Cardiology dbr:Foregut dbr:Glutamate_carboxypeptidase_II dbr:Hindgut dbr:Stomach dbc:Companies_based_in_Auvergne-Rhône-Alpes dbc:Pharmaceutical_companies_of_France dbc:French_companies_established_in_2002 dbc:Pharmaceutical_companies_established_in_2002 dbr:Chelation dbr:Chemotherapy dbr:Therapy dbr:Positron_emission_tomography dbr:Neuroendocrine_tumor dbr:Octreotide dbr:Oncology dbr:Radionuclide dbr:Radionuclide_therapy dbr:Rectum dbr:Somatostatin dbr:Neurology dbr:Diseases dbr:Lutetium dbr:Intestines dbr:Stefano_Buono dbr:PET_radiotracer dbr:Molecular_Imaging dbr:Neuroendocrine dbr:Radioisotope dbr:GEP-NET dbr:Gastrointestinal_stromal_tumors dbr:Diagnostic_imaging dbr:Sidonie_Golombowski-Daffner dbr:Neuroendocrine_tumors |
| dbp:industry | dbr:Pharmaceutical_industry |
| dbp:keyPeople | Sidonie Golombowski-Daffner, Chairperson and President (en) |
| dbp:location | Saint-Genis-Pouilly, France (en) |
| dbp:name | Advanced Accelerator Applications (en) |
| dbp:numEmployees | >1000 (en) |
| dbp:parent | dbr:Novartis |
| dbp:products | Gluscan, Dopaview, Fluorochol/Aaacholine, Netspot, Somakit Toc (en) |
| dbp:wikiPageUsesTemplate | dbt:Infobox_company dbt:Official_website dbt:Reflist dbt:See_also dbt:Start_date dbt:URL |
| dct:subject | dbc:Companies_based_in_Auvergne-Rhône-Alpes dbc:Pharmaceutical_companies_of_France dbc:French_companies_established_in_2002 dbc:Pharmaceutical_companies_established_in_2002 |
| gold:hypernym | dbr:Group |
| rdf:type | owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 yago:Abstraction100002137 yago:Company108058098 yago:DrugCompany108002578 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity dbo:Band dbo:Organisation yago:SocialGroup107950920 yago:WikicatPharmaceuticalCompanies |
| rdfs:comment | Advanced Accelerator Applications (AAA), (NASDAQ: AAAP) es un grupo farmacéutico especializado en el campo de la Medicina Nuclear. El grupo opera en los tres segmentos principales de la Medicina Nuclear (PET, SPECT y Terapia) para el diagnóstico y tratamiento de patologías graves en los campos de oncología (cáncer), neurología, cardiología y enfermedades infecciosas e inflamatorias. (es) Advanced Accelerator Applications, kurz AAA, ist ein pharmazeutisches Unternehmen, spezialisiert auf dem Gebiet der Nuklearmedizin. Die Gruppe agiert in allen drei Segmenten der molekularen Nuklearmedizin (PET, SPECT und Therapie) zur Diagnose und Behandlung schwerer Erkrankungen in den Bereichen Onkologie (Krebs), Neurologie, Kardiologie, Infektionskrankheiten und entzündlichen Erkrankungen. (de) Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases. (en) Advanced Accelerator Applications (AAA) (NASDAQ: AAAP) est un groupe pharmaceutique spécialisé en médecine nucléaire moléculaire. L’activité du groupe est axée sur les 3 segments de la médecine nucléaire moléculaire (la TEP/PET, la TEMP/SPECT et la thérapie) pour le diagnostic et le traitement de maladies oncologiques (cancer), neurologiques, cardiologiques, infectieuses et inflammatoires. (fr) |
| rdfs:label | Advanced Accelerator Applications (en) Advanced Accelerator Applications (de) Advanced Accelerator Applications (es) Advanced Accelerator Applications (fr) |
| rdfs:seeAlso | dbr:Peptide_receptor_radionuclide_therapy |
| owl:sameAs | freebase:Advanced Accelerator Applications yago-res:Advanced Accelerator Applications wikidata:Advanced Accelerator Applications dbpedia-de:Advanced Accelerator Applications dbpedia-es:Advanced Accelerator Applications dbpedia-fa:Advanced Accelerator Applications dbpedia-fr:Advanced Accelerator Applications https://global.dbpedia.org/id/ehq8 |
| skos:closeMatch | http://www.grid.ac/institutes/grid.476136.1 |
| prov:wasDerivedFrom | wikipedia-en:Advanced_Accelerator_Applications?oldid=1105561227&ns=0 |
| foaf:homepage | http://www.adacap.com |
| foaf:isPrimaryTopicOf | wikipedia-en:Advanced_Accelerator_Applications |
| foaf:name | Advanced Accelerator Applications (en) |
| is dbo:knownFor of | dbr:Stefano_Buono |
| is dbo:wikiPageDisambiguates of | dbr:AAA |
| is dbo:wikiPageRedirects of | dbr:Advanced_Accelerator_Applications_(AAA) |
| is dbo:wikiPageWikiLink of | dbr:Lutetium_(177Lu)_oxodotreotide dbr:BIOTECanada dbr:Novartis dbr:AAA dbr:AAAP dbr:Advanced_Accelerator_Applications_(AAA) dbr:Stefano_Buono dbr:Right-to-try_law |
| is foaf:primaryTopic of | wikipedia-en:Advanced_Accelerator_Applications |